Halofuginone is a low molecular weight quinazolinone alkaloid that acts as an inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression. It is being developed as a pharmaceutical active ingredient for research into fibrotic conditions and cancer metastasis.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Halofuginone?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Halofuginone hydrobromide
pharmaceutical raw material
Halofuginone lactate
pharmaceutical raw material
Umeclidinium bromide
pharmaceutical raw material
Neurokinin B
pharmaceutical raw material
Olodaterol hydrochloride
pharmaceutical raw material
Tecovirimat
pharmaceutical raw material
(-)-Halofuginone
pharmaceutical raw material
7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one
LVASCWIMLIKXLA-CABCVRRESA-N
C1C[C@@H]([C@H](NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
Sourcing Halofuginone?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.